Table 1, continued
	Patient 7	Patient 8	Patient 9	Patient 10	Patient 11	Patient 12
Age	19 years	17 years	29 years	43 years	30 years	52 years
Gender	Female	Female	Male	Male	Female	Male
Country	USA	USA	Australia	UK	UK	USA
First dose	Pfizer-BioNTech	Pfizer-BioNTech	Oxford-AstraZeneca	Pfizer-BioNTech	Oxford-AstraZeneca	Pfizer-BioNTech
Second dose	Pfizer-BioNTech	Pfizer-BioNTech	–	Pfizer-BioNTech	–	Pfizer-BioNTech
Third dose	–	–	–	Pfizer-BioNTech	–	–
POTS Symptom onset	18 days post second dose	3 weeks post second dose	4 days post first dose	1 to 2 weeks post second dose; 2–3 days post third dose	6 hours post first dose	After second dose
Symptoms	Dizziness, headache, nausea, bloating, excessive sweating, and fatigue	Syncope, fatigue, chest tightness, nausea, and heat intolerance	Intermittent paraesthesia, palpitations, racing hearbeat, dizziness, and worsening of paraesthesia and skin colour	Dizziness, leg weakness, light-headedness, brain fog, word-finding difficulties	Dizziness, nausea, weakness, bradykinesia, brain fog, early waking, fatigue, “jelly-legs”, changes to walking gait,	Burning and stabbing feeling, orthostatic intolerance, syncope, supraventricular tachycardia, tinnitus
Other medical conditions	None	None	None	None	Patient uses Naproxen, Lansoprazole, Dihydrocodeine, Melatonin	–
Past medical history	Not significant	Not significant	Not significant	Suspected COVID-19 infection (8 months before vaccination)	Fatigue and sleep disturbances	–
Previously known reactions to other vaccines	–	–	–	–	–	–
Medical Interventions	Salt tablets and Propranolol	Scopolamine patches, Salt tablets and Propranolol	5-week course of steroid (no effect); lifestyle modifications	Intramusular hydroxocobalamin followed by oral cyanocobalamin	Intramusular hydroxocobalamin therapy	Nadolol, Gabapentin, Amitriptyline, and trazodone (no effect); Five plasma exchange sessions
Resolution	Patient reported improvement in symptoms	Patient reported improvement in symptoms	Patient has some improvement still 6 months post treatment start	Eight weeks from treatment	Patient reported improvement in symptoms	Patient reported improvement in symptoms
Reference	Eldokla and Numan [7]	Eldokla and Numan [7]	Karimi [8]	Carroll et al., [9]	Carroll et al., [9]	Schelke et al.,